Distribution according to histologic type and outcome by gender and age group in Taiwanese patients with lung carcinoma

Cancer

Volumn 103, Issue 12, 2005, Pages 2566-2574

  Chen, Kuan Yu ^a   Chang, Chia Hsuin ^a   Yu, Chong Jen ^a   Kuo, Sow Hsong ^a   Yang, Pan Chyr ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Age; Gender; Lung carcinoma; Prognosis; Survival

Indexed keywords

ANTINEOPLASTIC AGENT;

ADENOCARCINOMA; ADOLESCENT; ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CELL TYPE; CONFIDENCE INTERVAL; CYTOLOGY; FEMALE; GROUPS BY AGE; HAZARD ASSESSMENT; HISTOLOGY; HUMAN; HUMAN TISSUE; LARGE CELL CARCINOMA; LUNG CARCINOMA; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; SEX DIFFERENCE; SQUAMOUS CELL CARCINOMA; TAIWAN; TIME; UNDIFFERENTIATED CARCINOMA;

ADENOCARCINOMA; ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; CARCINOMA, LARGE CELL; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SMALL CELL; CARCINOMA, SQUAMOUS CELL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; SEX DISTRIBUTION; SURVIVAL RATE; TAIWAN; TREATMENT OUTCOME;

EID: 20444376137     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.21087     Document Type: Article

References (47)

1. Wingo PA, Ries LA, Giovino GA, et al. Annual report to the nation of the status of cancer, 1973-1996, with a special section on lung cancer and tobacco smoking. J Natl Cancer Inst. 1999;91:675-690.
2. Yang SP, Luh KT, Yang PC. New developments in diagnosis and management of lung cancer. Respirology. 1996;1:37-46.
3. Magrath I, Litvak J. Cancer in developing countries: opportunity and challenge. J Natl Cancer Inst. 1993;85:862-866.
4. Chen CJ, Wu HY, Chuang YC, et al. Epidemiologic characteristics and multiple risk factors of lung cancer in Taiwan. Anticancer Res. 1990;10:971-976.
5. Yang SP, Luh KT, Kuo SH, Lin CC. Chronologic observation of epidemiologic characteristics in Taiwan, with etiological consideration a 30 year consecutive study. Jpn J Clin Oncol. 1984;14:7-19.
6. Nugent WC, Edney MT, Hammerness PG, Dain BJ, Maurer LH, Rigas JR. Non-small cell lung cancer at the extremes of age: impact on diagnosis and treatment. Ann Thorac Surg. 1997;63:193-197.
7. Ramalingam S, Pawlish K, Gadgeel S, Demers R, Kalemkerian GP. Lung cancer in young patients: analysis of a Surveillance, Epidemiology, and End Results database. J Clin Oncol. 1998;16:651-657.
8. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1999. CA Cancer J Clin. 1999;49:8-31.
9. Alexious C, Onyeaka CV, Beggs D, et al. Do women live longer following lung resection for carcinoma? Eur J Cardiothorac Surg. 2002;21:319-325.
10. Ferguson MK, Wang JH, Hoffman PC, et al. Sex-associated differences in survival of patients undergoing resection for lung cancer. Ann Thorac Surg. 2002;21:245-250.
11. Burkhart HM, Allen MS, Nicols FC III, et al. Results of enbloc resection for bronchogenic carcinoma with chest wall invasion. J Thorac Cardiovasc Surg. 2002;123:670-675.
12. DeCaro L, Benfield JR. Lung cancer in young persons. J Thorac Cardiovasc Surg. 1982;83:372-376.
13. Antkowiak JG, Regal AM, Takita H. Bronchogenic carcinoma in patients under age 40. Ann Thorac Surg. 1989; 47:391-393.
14. McDuffie HH, Klaassen DJ, Dosman JA. Characteristics of patients with primary lung cancer diagnosed at age 50 years or younger. Chest. 1989;96:1298-1301.
15. Sugio K, Ishida T, Kaneko S, Ishida T, Sugimachi K. Surgically resected lung cancer in young adults. Ann Thorac Surg. 1992;53:127-131.
16. Green LS, Fortoul TI, Ponciano G, Robles C, Rivero O. Bronchogenic cancer in patients under 40 years old: the experience of a Latin American country. Chest. 1993;104:1477-1481.
17. Shimono T, Hayashi T, Kimura M, et al. Surgical treatment of primary lung cancer in patients less than 40 years of age. J Clin Oncol. 1994;12:981-985.
18. Pemberton JH, Nagorney DM, Gilmore JC, Taylor WF, Bernatz PE. Bronchogenic in patients younger than 40 years. Ann Thorac Surg. 1983;36:509-513.
19. Bourke W, Milstein D, Giura R, et al. Lung cancer in young adults. Chest. 1992;102:1723-1729.
20. Roviaro GC, Varoli F, Zanni P, Fascianella A, Pezzuoli G. Lung cancer in the young. Chest. 1985;87:456-459.
21. Icard P, Regnard JF, de Napoli S, Rojas-Miranda A, Dartevelle P, Levasseur P. Primary lung cancer in young patients: a study of 82 surgically treated patients. Ann Thorac Surg. 1992;54:99-103.
22. Capewell S, Wathen CG, Sankaran R, Sudlow MF. Lung cancer in young patients. Respir Med. 1992;86:499-502.
23. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest. 1997;111:1710-1717.
24. [No authors listed.] The World Health Organization histological typing of lung tumors. 2nd ed. Am J Clin Pathol. 1982;77:123-136.
25. Vincent RG, Takita H, Lane WW, Gutierrerz AC, Picken JW. Surgical therapy of lung cancer. J Thorac Cardiovasc Surg. 1976;71:581-591.
26. Stanley KE. Prognostic factors for survival in patients with in operable lung cancer. J Nat Cancer Inst. 1980;65:25-32.
27. Lanzotti VJ, Tomas DR, Boyle LE, Smith TL, Gehan EA, Samuels ML. Survival with inoperable lung cancer. Cancer. 1977;39:303-313.
28. O'Connell JP, Kris MG, Gralla RJ, et al. Frequency and prognostic importance of pretreatment clinical characteristics in patients with advanced non small cell lung cancer treated with combination chemotherapy. J Clin Oncol. 1986;4:1604-1614.
29. Travis WD, Lubin J, Ries L, Sdevesa S. United States lung carcinoma incidence trend. Cancer. 1996;77:2464-2470.
30. Skuladottir H, Olsen JH, Hirsch FR. Incidence of lung cancer in Denmark: historical and actual status. Lung Cancer. 2000; 27:107-118.
31. Thun MJ, Lally CA, Flannery JT, Calle EE, Flanders WD, Heath CW Jr. Cigarette smoking and changes in histopathology of lung cancer. J Natl Cancer Inst. 1997;89:1580-1586.
32. Hoffmann D, Djordjevic MV, Hofmann I. The changing cigarette. Prev Med. 1997;26:427-434.
33. Xie L, Ugnat AM, Morriss J, Semenciw R, Mao Y. Histology-related variation in the treatment and survival of patients with lung carcinoma in Canada. Lung Cancer. 2003;42:127-139.
34. Lienert T, Serke M, Schonfeld N, Loddenkemper R. Lung cancer in young females. Eur Respir J. 2000;16:986-990.
35. Li X, Mutanen P, Hemminki K. Gender-specific incidence trends in lung cancer by histological type in Sweden, 1958-1996. Eur J Cancer Prev. 2001;10:227-235.
36. Morita T. A statistical study of lung cancer in the annual of pathological autopsy cases in Japan, from 1958 to 1997, with reference to time trends of lung cancer in the world. Jpn J Cancer Res. 2002;93:15-23.
37. Choi JH, Chung HC, Yoo NC, et al. Changing trends in histologie types of lung cancer during the last decade (1981-1990) in Korea: a hospital-based study. Lung Cancer. 1994; 10:287-296.
38. Fukuoka M, Yano S, Giaccone G, et al. A multi-institutional randomized Phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol. 2003;21:2237-2246.
39. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA. 2003;290:2149-2158.
40. Janne PA, Gurubhagavatula S, Yeap BY, et al. Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, "Iressa") on an expanded access study. Lung Cancer. 2004;44:221-230.
41. Mirier VA, Kris MG, Shah N, et al. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol. 2004;22:1103-1109.
42. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350:2129-2139.
43. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304:1497-1500.
44. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated, with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA. 2004;101: 13306-13311.
45. Osterlind K, Sorensen JB. Prognostic factors. In: Aisner J, Arriagada R, Green MR, et al., editors. Comprehensive textbook of thoracic oncology. Baltimore: Williams & Wilkins, 1996:316-335.
46. Feld R, Sagman U, LeBlanc M. Staging and prognostic factors: small cell lung cancer. In: Pass HI, Mitchell JB, Johnson DH, Turrisi AT, editors. Lung cancer: principles and practice. Philadelphia: Lippincott-Raven, 1996:495-509.
47. Moore DF, Lee JS. Staging and prognostic factors: non-small lung cancer. In: Pass HI, Mitchell JB, Johnson DH, Turrisi AT, editors. Lung cancer: principles and practice. Philadelphia: Lippincott-Raven, 1996:481-494.